A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

BACKGROUND: The purpose of this prospective study was to assess the ability of plasma vascular endothelial growth factor-A short isoforms (pVEGF-Asi) to predict bevacizumab (BV) efficacy and to explore other circulating biomarkers in metastatic colorectal cancer (mCRC) patients treated with modified...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamoto, W., Sakai, K., Makiyama, A., Yamamoto, Y., Shitara, K., Denda, T., Izawa, N., Nakano, Y., Nishina, T., Esaki, T., Hara, H., Miura, Y., Boku, N., Yamazaki, K., Hironaka, S., Misumi, T., Hyodo, I., Muro, K., Nishio, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808456/
https://www.ncbi.nlm.nih.gov/pubmed/36502778
http://dx.doi.org/10.1016/j.esmoop.2022.100592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808456/
https://www.ncbi.nlm.nih.gov/pubmed/36502778
http://dx.doi.org/10.1016/j.esmoop.2022.100592

Ejemplares similares